Long-term follow-up of psilocybin-facilitated smoking cessation.

ABSTRACT:

Background

A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone.

Objectives

To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration.

Methods

The present report describes biologically verified smoking abstinence outcomes of the previous pilot study at ≥12 months, and related data on subjective effects of psilocybin.

Results

All 15 participants completed a 12-month follow-up, and 12 (

SUBMITTER: Johnson MW 

PROVIDER: S-EPMC5641975 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature